Lüthgens M, Schlegel G
Cancer Detect Prev. 1983;6(1-2):51-9.
In the Radiology Clinic of our hospital at present more than 2000 patients have been under surveillance using carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) as markers. The available results have indicated that a combination of both parameters may be applicable in monitoring therapy and in the surveillance thereafter in a variety of cancer sites. It was advantageous to utilize a common index derived from the CEA and TPA serum values after natural logarithmic transformation. Hence, discrimination could be achieved between patients without evidence of disease, and those with progressive disease, eg, in breast cancer with a probability of 95%. The following probabilities were established in 10 other tumor sites: colorectum, 96%; seminoma, 94%; lung, 93%; prostate and bladder, 90%; hypernephroma, 87%; sarcoma, 86%; thyroid, 84%; melanoma, 83%; head and neck, 77%; female genitals, 76%. CEA alone was not applicable in some localized tumors, such as seminoma, melanoma, hypernephroma, and sarcoma. Also, in monitoring patients under chemotherapy, it was established in the follow-up of different cancer sites that TPA was superior to CEA. A concordance with the clinical efficacy of the chemotherapy was found for TPA in 94%, for CEA in 54%, and for both markers in 52%. Thus, as a typical proliferation antigen, TPA appeared to react with a greater sensitivity than CEA on the cytostatic effect of chemotherapy.
目前，在我院放射科，已有2000多名患者接受了以癌胚抗原（CEA）和组织多肽抗原（TPA）作为标志物的监测。现有结果表明，这两个参数的联合应用可能适用于多种癌症部位治疗的监测及后续的随访。对CEA和TPA血清值进行自然对数转换后，利用由此得出的一个共同指标是有益的。因此，在无疾病证据的患者和疾病进展的患者之间能够实现区分，例如在乳腺癌患者中，区分概率可达95%。在其他10个肿瘤部位也确定了以下概率：结直肠癌为96%；精原细胞瘤为94%；肺癌为93%；前列腺癌和膀胱癌为90%；肾癌为87%；肉瘤为86%；甲状腺癌为84%；黑色素瘤为83%；头颈部癌为77%；女性生殖器癌为76%。单独使用CEA不适用于某些局限性肿瘤，如精原细胞瘤、黑色素瘤、肾癌和肉瘤。此外，在监测接受化疗的患者时，对不同癌症部位的随访发现，TPA优于CEA。TPA与化疗临床疗效的一致性为94%，CEA为54%，两种标志物均为52%。因此，作为一种典型的增殖抗原，TPA在化疗的细胞抑制作用方面似乎比CEA反应更敏感。
